| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | FN; CIG; FNZ; MSF; ED-B; FINC; GFND; LETS; GFND2 |
| Entrez GeneID | 2335 |
| clone | 2F4 |
| WB Predicted band size | 262.6kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human FN1 expressed in E. Coli. |
| Formulation | Ascitic fluid containing 0.03% sodium azide. |
+ +
以下是关于CDK18抗体的3-4篇文献示例及其摘要内容概括：
---
1. **文献名称**: "CDK18 regulates cell cycle progression through CDC25C phosphorylation in response to DNA damage"
**作者**: Smith J, et al.
**摘要**: 本研究利用特异性CDK18抗体揭示了该激酶在DNA损伤应答中的作用。实验表明，CDK18通过磷酸化CDC25C调控G2/M检查点，影响细胞周期阻滞，提示其在基因组稳定性中的潜在功能。
2. **文献名称**: "Development and validation of a monoclonal antibody targeting CDK18 for cancer biomarker studies"
**作者**: Zhang L, et al.
**摘要**: 作者开发了一种高特异性抗CDK18单克隆抗体，并验证其在乳腺癌组织中的表达。结果显示CDK18在肿瘤样本中过表达，且与患者预后不良相关，支持其作为癌症生物标志物的潜力。
3. **文献名称**: "CDK18 modulates transcriptional elongation in a kinase-dependent manner"
**作者**: Johnson R, et al.
**摘要**: 通过免疫沉淀结合CDK18抗体，研究发现CDK18与RNA聚合酶II相互作用，调控基因转录延伸过程。其激酶活性影响多种致癌基因表达，提示CDK18在肿瘤发生中的转录调控作用。
4. **文献名称**: "Functional characterization of CDK18 antibodies in neurodegenerative models"
**作者**: Lee S, et al.
**摘要**: 该研究利用CDK18抗体探究其在神经退行性疾病中的表达变化。实验显示，CDK18在小鼠阿尔茨海默模型中表达上调，可能通过异常细胞周期重激活参与神经元死亡机制。
---
注：上述文献信息为示例性概括，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。如需具体文献，建议补充时间范围或研究领域进一步筛选。
CDK18 (Cyclin-Dependent Kinase 18) is a serine/threonine kinase belonging to the CDK family, which regulates critical cellular processes such as cell cycle progression, transcription, and RNA processing. Unlike canonical CDKs (e.g., CDK1. CDK2) directly driving cell cycle phases, CDK18 is classified as a transcriptional CDK, interacting with cyclin L to modulate RNA polymerase II activity and mRNA synthesis. It plays roles in transcription elongation, DNA damage response, and cell differentiation. Dysregulation of CDK18 has been implicated in cancers, including breast, liver, and colorectal cancers, where its overexpression or altered activity may influence tumor growth, metastasis, or therapeutic resistance.
CDK18 antibodies are essential tools for studying its expression, localization, and functional roles. They enable detection via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in biomarker research and mechanistic studies. Some antibodies target specific phosphorylated forms to assess activation status. While CDK18 is less characterized than other CDKs, emerging studies highlight its potential as a therapeutic target, driving demand for validated antibodies. Challenges include ensuring specificity due to high homology among CDK family members. Commercial CDK18 antibodies are typically developed using recombinant protein fragments or peptide immunogens, with validation in knockdown/knockout models to confirm reliability.
×
